The big picture: While research continues, psychedelic medicine could reshape the future of healthcare and wellness. As momentum builds, scientists, startups, investors, and big pharma are plotting their next move.

Because psychedelics are basically an end-of-the-world “technology-gift bundle”, they do not fit into a paradigm that is essentially still pretending that we can continue business as usual.

Startup culture cannot extricate itself from corporate values, no matter how whitewashed the outside is with clever branding.

Psychedelics-as-a-service. Unlike cannabis, proponents are quick to warn that psychedelics aren’t a commodity, they’re a service. Marijuana is a commodity that can be cultivated and distributed. Psychedelics, on the other hand, rely on delivery — or the service component.